Recent Approvals of CAR T-Cell Therapy in R/R Multiple Myeloma

EP: 1.Patient Profile: A 60-Year-Old Woman with Later Relapsed/Refractory Multiple Myeloma

Now Viewing

EP: 2.Recent Approvals of CAR T-Cell Therapy in R/R Multiple Myeloma

EP: 3.The Role of Stem Cell Transplant in R/R Multiple Myeloma

EP: 4.Treating Patients who Progress Following CAR T in R/R MM

EP: 5.Community-Based Care: Key Strategies for Effective R/R MM Management

EP: 6.Future Perspectives on the Treatment of R/R Multiple Myeloma

Case: A 60-Year-Old Woman with Later Relapsed/Refractory Multiple Myeloma

Clinical Presentation:

• A 60-year-old woman who was previously diagnosed 3 years ago with R-ISS stage 2/R2-ISS stage III IgG-lambda multiple myeloma presents to his oncologist after two prior treatment regimens.
  • Lives in a rural community

Prior Treatments:

• Patient received previous treatments with:
  • D-VRd followed by ASCT with lenalidomide maintenance.
  • Elo-Pd

Follow up and Clinical Workup at Relapse:

• Ca 12.5 mg/dL; SCr 2.5 mg/dL
• Hgb 8.2 g/dL; LDH 290 U/L; Albumin 2.8 g/dL
• Beta-2 microglobulin: 6 mg/dL
• BM Biopsy: 65% lambda light chain restricted.
• sIFE, IgG lambda present
• M protein 5.2 g/dL; sFLC kappa 5 mg/dL; sFLC lambda 560 mg/dL
• Lambda/Kappa ratio, 112
• Repeat Imaging:
  • PET/CT scan showed no additional lesions.
• ECOG PS 1
• After discussion with his clinical team, the patient begins evaluations for CAR T referral.
  • Patient ultimately proceeded to ide-cel CAR T-cell infusuion.
    • Achieved stringent CR at day 30.

Video content above is prompted by the following question:

• Following the FDA’s ODAC meetings and recent approvals of CAR T in early relapsed/refractory MM, what ongoing studies may further support the use of CAR T in these patients?